Sarah B.  Cavanaugh net worth and biography

Sarah Cavanaugh Biography and Net Worth

Ms. Cavanaugh joined Celldex in August 2012 as Vice President of Investor Relations and Corporate Communications. Prior to joining Celldex, she served from 2007 to 2012 as a Vice President at MacDougall Biomedical Communications, a strategic communications and investor relations firm for the life sciences industry, where she developed and implemented programs for more than 20 biopharmaceutical companies and served as the in-house oncology expert. Ms. Cavanaugh has served in a number of leadership positions in the health care and life sciences industry, including Director of Corporate Communications for Point Therapeutics, an oncology-focused biotech company, and Director of Corporate Communications for Fallon Community Health Plan, a leading Massachusetts managed care organization. She began her health care career at the American Cancer Society, holding various positions providing leadership in physician education, corporate communications, government relations and marketing. She completed her tenure there as Division Communications and Marketing Director for the Mid-South Division, where she was responsible for managing the efforts of marketing and communications staff across six states. Throughout her career, Ms. Cavanaugh has played a leadership role in organizational development and employee relations/communication. Ms. Cavanaugh received her B.A. from the University of New Hampshire.

What is Sarah B. Cavanaugh's net worth?

The estimated net worth of Sarah B. Cavanaugh is at least $33,435.36 as of August 17th, 2022. Ms. Cavanaugh owns 1,284 shares of Celldex Therapeutics stock worth more than $33,435 as of December 17th. This net worth evaluation does not reflect any other investments that Ms. Cavanaugh may own. Learn More about Sarah B. Cavanaugh's net worth.

How old is Sarah B. Cavanaugh?

Ms. Cavanaugh is currently 49 years old. There are 9 older executives and no younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics is Prof. Joseph P. Schlessinger Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 79 years old. Learn More on Sarah B. Cavanaugh's age.

How do I contact Sarah B. Cavanaugh?

The corporate mailing address for Ms. Cavanaugh and other Celldex Therapeutics executives is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. Celldex Therapeutics can also be reached via phone at (908) 454-7120 and via email at [email protected]. Learn More on Sarah B. Cavanaugh's contact information.

Has Sarah B. Cavanaugh been buying or selling shares of Celldex Therapeutics?

Sarah B. Cavanaugh has not been actively trading shares of Celldex Therapeutics within the last three months. Most recently, Sarah Cavanaugh sold 31,312 shares of the business's stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $36.73, for a transaction totalling $1,150,089.76. Following the completion of the sale, the senior vice president now directly owns 1,284 shares of the company's stock, valued at $47,161.32. Learn More on Sarah B. Cavanaugh's trading history.

Who are Celldex Therapeutics' active insiders?

Celldex Therapeutics' insider roster includes Sarah Cavanaugh (SVP), Elizabeth Crowley (VP), Freddy Jimenez (SVP), Samuel Martin (CFO), Anthonly Marucci (President & CEO), and Diane Young (SVP). Learn More on Celldex Therapeutics' active insiders.

Are insiders buying or selling shares of Celldex Therapeutics?

In the last year, Celldex Therapeutics insiders bought shares 1 times. They purchased a total of 11,500 shares worth more than $308,430.00. In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 266,332 shares worth more than $9,155,821.33. The most recent insider tranaction occured on November, 11th when CEO Anthony S Marucci bought 11,500 shares worth more than $308,430.00. Insiders at Celldex Therapeutics own 3.8% of the company. Learn More about insider trades at Celldex Therapeutics.

Information on this page was last updated on 11/11/2024.

Sarah B. Cavanaugh Insider Trading History at Celldex Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/17/2022Sell31,312$36.73$1,150,089.761,284View SEC Filing Icon  
12/8/2021Sell7,323$40.00$292,920.00View SEC Filing Icon  
See Full Table

Sarah B. Cavanaugh Buying and Selling Activity at Celldex Therapeutics

This chart shows Sarah Cavanaugh's buying and selling at Celldex Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Celldex Therapeutics Company Overview

Celldex Therapeutics logo
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Read More

Today's Range

Now: $26.04
Low: $25.71
High: $26.47

50 Day Range

MA: $27.19
Low: $23.31
High: $31.32

2 Week Range

Now: $26.04
Low: $22.93
High: $53.18

Volume

704,807 shs

Average Volume

887,484 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57